AbbVie Inc (ABBV)vsDentsply Sirona Inc (XRAY)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
XRAY
Dentsply Sirona Inc
$11.48
-2.55%
HEALTHCARE · Cap: $2.30B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1562% more annual revenue ($61.16B vs $3.68B). ABBV leads profitability with a 6.9% profit margin vs -16.3%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
XRAY
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+77.0%
Fair Value
$59.47
Current Price
$11.48
$47.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Operating margin of 1.8%
ROE of -36.4% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : XRAY
The strongest argument for XRAY centers on PEG Ratio, Price/Book. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : XRAY
The primary concerns for XRAY are Operating Margin, Return on Equity, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while XRAY is a turnaround play — different risk/reward profiles.
XRAY carries more volatility with a beta of 1.00 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 56/100). XRAY offers better value entry with a 77.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Dentsply Sirona Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?